Pacific Biomarkers, Inc. (PBI) (OTC.BB: PBMC)

Pacific Biomarkers, Inc provides specialty reference and clinical laboratory services primarily to the pharmaceutical, biotechnology, and diagnostics industries in the United States. The company’s services support pharmaceutical, biotechnology, and laboratory diagnostic manufacturers in the conduct of human clinical research, for use in drug and diagnostic product development efforts. Its services include specialty reference laboratory services, including clinical study testing services, development of laboratory reference methods, development of clinical trial protocols, and contract research and development in the areas of cardiovascular disease, diabetes, metabolic syndrome, obesity, and bone and joint diseases. The company also offers central laboratory services for multi-center clinical trials that comprise project management and routine safety lab tests. In addition, Pacific Biomarkers provides clinical biomarker services for biomarker assay development, immunogenicity testing, and multiplex testing. It was formerly known as Pacific Biometrics, Inc. and changed its name to Pacific Biomarkers, Inc. in December 2009. The company was founded in 1996 and is based in Seattle, Washington.